Recombinant human VSIG8 Protein, Fc tag, 100 µg

Background
V-set and immunoglobulin domain containing 8 (VSIG8), also known as C1orf204, is a type I transmembrane protein of the B7 family within the Ig superfamily. VSIG8 was identified from proteomic analysis of human hair shafts. It is expressed in the hair follicle and shaft, superficial layers of the nail matrix, and superficial layers of oral epithelium.

Source
Recombinant human VSIG8, Fc tag (VS8-H5250) is expressed from human 293 cells (HEK293). It contains AA Val 22 - Gly 263 (Accession # NP_001013683.1).
Predicted N-terminus: Val 22

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 53.7 kDa. As a result of glycosylation, the protein migrates as 55-65 kDa under reducing (R) condition, and 110-130 kDa under non-reducing (NR) condition (SDS-PAGE).

Endotoxin
Less than 1.0 EU per μg by the LAL method.
 
Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20^°C to -70^°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Clinical and Translational Updates

(1) "Identification of genetic profile and biomarkers involved in acute respiratory distress syndrome"
Cao, Li, Xin et al
Intensive Care Med (2024) 50 (1), 46-55
(2) "VSIG-3 as a ligand of VISTA inhibits human T-cell function"
Wang, Wu, Manick et al
Immunology (2019) 156 (1), 74-85
(3) "A small molecule inhibitor of VSIG-8 prevents its binding to VISTA"
Chen, Qie, Hu et al
Invest New Drugs (2022) 40 (4), 690-699
Showing 1-3 of 5 papers.